Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized study of vupanorsen in statin-treated participants with dyslipidemia
2020-002796-35Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing Vupanorsen dose-ranging arms with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in non-HDL-C. Started Nov 2020; status: completed.
02
Drugs
vupanorsen
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on 2020-002796-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002796-35.